Clinical Trials
18 trialsNCT06670911 2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2 Recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06531447 2024-08-01
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
Phase 2 Active not recruiting
NCT06066216 2024-01-23
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT06149767 2023-11-29
Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05832827 2023-10-23
Artemis
National Cancer Center, Japan
Phase 2 Recruiting
NCT05751265 2023-06-22
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT05013697 2021-08-19
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
Henan Cancer Hospital
Phase 2 Unknown
NCT02414685 2020-08-07
TIP
National Cancer Institute, Slovakia
Phase 2 Completed
NCT02924909 2018-03-20
QUIMERA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT01843829 2014-03-24
NeoSCOPE
Velindre NHS Trust
Phase 2 Unknown
NCT00532857 2012-01-04
PGH
National Cancer Center, Korea
Phase 2 Completed
NCT01169870 2012-01-04
Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
National Cancer Center, Korea
Phase 2 Withdrawn
NCT00532285 2011-06-23
Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer
National Cancer Center, Korea
Phase 2 Terminated
NCT00453167 2010-07-12
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT00453323 2010-07-12
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
National Cancer Center, Korea
Phase 2 Unknown